<DOC>
	<DOC>NCT02584634</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.</brief_summary>
	<brief_title>Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)</brief_title>
	<detailed_description>This is a Phase 1b/2, open label, multi center, multiple dose, safety, pharmacokinetic and pharmacodynamic study of Group A and Group B in cohorts of adult patients with locally advanced or metastatic NSCLC.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Inclusion Criteria Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC Group A at least one prior regimen of therapy Group B any number of prior regimens. Mandatory tumor tissue available At least one measurable lesion ECOG Performance status 0 or 1 Adequate bone marrow, renal, liver and pancreatic function Negative pregnancy test for females of childbearing potential No prior therapy with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody. No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history No active infection requiring systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ALK</keyword>
	<keyword>avelumab</keyword>
	<keyword>crizotinib</keyword>
	<keyword>PF-06463922</keyword>
</DOC>